Alzheimer’s Disease New Treatments

A worldwide pursuit is under way to discover brand-new treatments to stop, slow or perhaps avoid Alzheimer’s. Due to the fact that brand-new drugs take years to produce from principle to market– and since drugs that seem promising in early-stage research studies might not work as hoped in large-scale trials– it is vital that Alzheimer’s and associated dementias research continue to speed up.

To make sure that the effort to discover much better treatments gets the focus it deserves, the Alzheimer’s Association funds scientists looking at new treatment techniques and supporters for more federal financing of Alzheimer’s research.

The wish for future drugs

Currently, there are five FDA-approved Alzheimer’s drugs that treat the symptoms of Alzheimer’s— momentarily assisting memory and thinking problems in about half of individuals who take them. However these medications do not treat the underlying causes of Alzheimer’s.

On the other hand, a number of the new drugs in development objective to modify the disease procedure itself, by impacting several of the many comprehensive brain changes that Alzheimer’s causes.

Alzheimer's disease. Brain comparison

Alzheimer’s disease. Brain comparison

These changes offer possible “targets” for brand-new drugs to stop or slow the progress of the disease. Numerous scientists believe effective treatment will ultimately involve a “mixed drink” of medications aimed at several targets, just like current state-of-the-art treatments for many cancers and AIDS.

Targets for future drugs

Over the last 30 years, researchers have made exceptional development in understanding healthy brain function and what fails in Alzheimer’s disease. The following are examples of promising targets for next-generation drug treatments under examination in existing research studies:

  • Beta-amyloid is the chief element of plaques, one hallmark Alzheimer’s brain abnormality. Researchers now have a detailed understanding of how this protein piece is clipped from its parent substance amyloid precursor protein (APP) by two enzymes– beta-secretase and gamma-secretase. Researchers are developing medications aimed at essentially every point in amyloid processing. This consists of stopping activity of beta-secretase enzyme; avoiding the beta-amyloid pieces from clumping into plaques; as well as using antibodies versus beta-amyloid to clear it from the brain.
  • Current drug in research that targets beta-amyloid: Solanezumab                 Solanezumab is a monoclonal antibody developed to decrease the level of beta-amyloid in the brain. These antibodies bind to beta-amyloid, preventing the development of plaques; solanezumab may also help bring excess beta-amyloid away from the brain. Several research studies of this drug are under way with the objective determining if solanezumab enhances individuals’ cognition (thinking and memory) and operating. Some individuals will undergo a brain scan called positron emission tomography (PET) to identify levels of beta-amyloid in the brain. (Drug is still in research; not readily available to the general public.)
  • Beta-secretase (BACE) is one of the enzymes that clips APP and makes it possible for beta-amyloid to form. Treatments that interrupt this process may reduce the amount of beta-amyloid in the brain and eventually intervene in the development of Alzheimer’s disease. Existing drug in research that targets beta-secretase: MK-8931. MK-8931 is a BACE inhibitor– it inhibits the ability of the beta-secretase enzyme to make beta-amyloid. At the Alzheimer’s Association International Conference ® 2013( AAIC ®), scientists reported that the drug significantly decreased beta-amyloid levels in individuals with mild-to-moderate Alzheimer’s. MK-8931 is being tested in two phase 3 clinical trials. (Drug is still in research; not readily available to the public.)
  • Tau protein is the primary component of tangles, the other trademark brain problem of Alzheimer’s. Tau protein helps keep the structure of a nerve cell, consisting of small tube-like structures called microtubules that deliver nutrients throughout the neuron. Scientists are examining systems to prevent tau protein from collapsing and twisting into tangles, a procedure that damages microtubules and, ultimately, the nerve cell itself.  Existing drug in research that targets tau protein: AADvac1. AADvac1 is a vaccine that stimulates the body’s body immune system to attack an abnormal form of tau protein that destabilizes the structure of neurons. If effective, it has the possible to assist stop the development of Alzheimer’s disease. At AAIC 2015, scientists reported that AADvac1 was safe and well endured by participants in a stage 1 scientific trial. (Drug is still in research; not available to the general public.)
  • Inflammation is another crucial Alzheimer’s brain problem. Both beta-amyloid plaques and tau tangles cause an immune response in the brain. Microglia are cells that serve as the first kind of immune defense in the brain. While microglia help clear beta-amyloid in the brain, they might end up being overactive in the existence of beta-amyloid and produce compounds that damage close-by cells.     Existing drug in research that targets inflammation: CSP-1103. CSP-1103 is a microglial modulator that aims to reduce inflammation in the brain. At AAIC 2013, researchers provided the results of a 90-week trial where people who had mild cognitive problems (MCI) were offered CSP-1103. Preliminary research studies proved to that CSP-1103 avoided beta-amyloid from being deposited on nerve cells and forming plaques. It also minimized problems with thinking and memory (cognition). The cognitive tests of individuals who had gotten involved for at least 64 weeks proved to statistically considerable enhancements in participants’ cognitive capabilities. (Drug is still in research; not available to the public.)
  • Insulin resistance in the brain is another common feature of Alzheimer’s disease. For reasons scientists do not completely comprehend, the brain ends up being resistant to the normal impacts of insulin, consisting of the conversion of glucose to energy that brain cells can use to sustain cell performance. Some research recommends that beta-amyloid reduces the body’s ability to use insulin. Other research has actually found reduced levels of insulin in the brain.  Current drug in research that targets insulin resistance: Intranasal insulin. Intranasal insulin is a therapy being checked in multiple research studies for its impacts on memory, believing and day-to-day working in people with MCI and mild-to-moderate Alzheimer’s disease. There is growing evidence that insulin plays a crucial function in keeping the brain healthy. Intranasal administration of insulin might help by increasing insulin signaling in the brain. (Drug is still in research; not readily available to the general public.)

Alzheimer’s prevention trials

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial

The A4 trial is studying the efficiency of solanezumab, a drug targeting beta-amyloid, in 1,150 symptom-free volunteers whose PET scans show abnormally high levels of beta-amyloid in the brain. High levels of beta-amyloid in the brain increase the risk for developing Alzheimer’s disease. Researchers hope that early intervention in people at increased risk of developing Alzheimer’s will prevent the cognitive decrease of this disastrous and ultimately fatal disease.


The TOMMORROW Trial consists of 3,500 asymptomatic people, some of whom have the Alzheimer’s risk gene apolipoprotein E e4 (APOE-e4) or the TOMM40 risk gene. The trial will have a look at whether the anti-diabetes drug pioglitazone can avoid mild cognitive disability due to Alzheimer’s disease. Research studies suggest that pioglitazone may reduce inflammation and beta-amyloid levels in the brain, improve blood circulation to the brain and increase the brain’s ability to use glucose to fuel nerve cells.

Dominantly Inherited Alzheimer Network Trial Unit (DIAN TU)

Anomalies on 3 genes are realised to cause an uncommon kind of Alzheimer’s disease that accounts for less than 1 percent of cases. When an individual has one of these anomalies, she or he has a 95 percent to 100 percent possibility of establishing Alzheimer’s. DIAN TU tracks changes in the brains of people with those rare Alzheimer’s gene anomalies who have not yet developed the disease. In addition, researchers are studying two drug prospects (gantenerumab and solanezumab) that might slow or stop brain changes and avoid symptoms like memory loss from occurring.

The Alzheimer’s Prevention Initiative (API)

Like DIAN TU, API tests treatments in individuals who have a gene mutation that causes Alzheimer’s, but have not yet established symptoms. Drugs that delay or prevent symptoms in people with genetic anomalies for Alzheimer’s may possibly postpone or prevent symptoms in people with the brain changes of Alzheimer’s who do not have these hereditary mutations. The API trial is studying the effects of crenezumab, an immune-based therapy. Crenezumab delivers antibodies versus beta-amyloid in an effort to reduce the unfavorable cognitive impacts of excess beta-amyloid.


We will be happy to hear your thoughts

      Leave a reply

      This site uses Akismet to reduce spam. Learn how your comment data is processed.